SLU-PP-332: The "Exercise in a Molecule" Compound — Promise vs Proof

SLU-PP-332 is an experimental small molecule that, in 2023, made headlines as a possible "exercise in a pill" after mice given it ran dramatically farther and gained far less fat without touching a treadmill. It is not a peptide and not a supplement; it is a synthetic activator of a family of cellular switches called the estrogen-related receptors (ERRs). The catch, and the whole point of this guide, is that every one of those striking results comes from mice, not people: SLU-PP-332 has never been in a human trial, has no human safety data, and is not approved by any regulator.

This page is the high-level map of the whole compound, written around one honest thesis: promise versus proof. We cover what SLU-PP-332 actually is, how the proposed "exercise mimetic" mechanism works, what the 2023 mouse studies really showed, where it sits on the evidence ladder (spoiler: the human rung is empty), the doses used in animals, the safety picture, and its research-chemical legal status. If you came here while comparing options for stamina, see how it stacks up against the field in our roundup of the best peptides for endurance and aerobic performance. Each section is a clear overview; adjacent rabbit holes (other exercise mimetics, how transcription factors work) stay shallow and link out, so this page stays a clean hub.

Key Takeaways

• SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) that switches on an exercise-like gene program in cells. It is a small molecule, not a peptide (ACS Chemical Biology, 2023).
• It is entirely preclinical: there are no human trials and no human safety data at all. Every result comes from mouse and lab studies, and the compound is not FDA-approved and is not a dietary supplement (University of Florida News, 2023).
• The "exercise in a pill" headline is from 2023 mouse research. Treated mice ran about 70% longer and 45% farther than untreated mice (University of Florida News, 2023).
• In obese mice, it cut fat gain and weight. Over roughly a month, treated obese mice lost about 12% of body weight and gained far less fat than untreated mice (Journal of Pharmacology and Experimental Therapeutics, 2024).
• It is not drug-ready. Researchers note poor drug-like properties (very low solubility, a short ~31-minute half-life in lab tests) and that it required injection in mice, so structural redesign is needed before any human study (International Journal of Biological Macromolecules, 2026).
• It is sold only as a research chemical. Vials are labeled "for research use only," there is no approved dose, and any human use is unstudied and unregulated.

What is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule that turns on the estrogen-related receptors (ERRs), a set of cellular control switches that govern how cells make and burn energy. It is not a peptide, not a hormone you are missing, and not a supplement: it is a designed research compound. Its name comes from Saint Louis University ("SLU"), where chemist Thomas Burris and colleagues developed it. It is studied as a possible "exercise mimetic," meaning a drug that triggers some of the body's responses to exercise.

Chemically, SLU-PP-332 is a small organic molecule (PubChem CID 5404083; CAS 303760-60-3), not a chain of amino acids, which is the single most common point of confusion. A peptide like BPC-157 is built from amino acids and usually injected because the gut would digest it; SLU-PP-332 is a classic "small molecule" of the kind most oral drugs are made from. Despite that, in the published studies it was given to mice by injection, because its own chemistry is not yet drug-like enough for reliable oral dosing (International Journal of Biological Macromolecules, 2026, retrieved 2026-06-16). If the broader category is new to you, our how peptides and small molecules signal in the body guide covers the foundations.

The single most important fact about SLU-PP-332 is its status: it is entirely preclinical. It exists in a small body of mouse and laboratory research and, separately, in an unapproved "research chemical" market. There is no approved use, no human trial, and no human safety record. Everything else in this guide should be read through that lens.

Citation capsule. SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ (not a peptide), developed in the lab of Thomas Burris and studied as a preclinical "exercise mimetic." It activates an ERRα-dependent aerobic exercise gene program in mice. It is not FDA-approved, has no human trial data, and is sold for research use only. Source: ACS Chemical Biology, 2023; PubChem CID 5404083; CAS 303760-60-3.

How does SLU-PP-332 work?

SLU-PP-332 works by switching on the estrogen-related receptors (ERRs), which act like a master dial for the cell's energy machinery, telling muscle and other tissues to build more mitochondria and burn more fat, the same program exercise normally activates. In plain terms, it nudges cells into an "I just worked out" state. This entire picture comes from mouse and cell studies, not human ones.

The ERRs are transcription factors, proteins that switch genes on and off. SLU-PP-332 binds and activates all three (ERRα, ERRβ, ERRγ), which is why it is called a pan-agonist. In a 2023 study, the team reported that the compound "induces an ERRα-dependent acute aerobic exercise" gene response, the molecular signature your muscles produce after endurance training (ACS Chemical Biology, "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity," 2023, retrieved 2026-06-16). Downstream, that program is linked to more mitochondria (the cell's power plants), greater fat and sugar oxidation, and a shift toward fatigue-resistant "oxidative" muscle fibers.

What makes this interesting biologically is that ERRα sits near the top of the cell's energy-control hierarchy, working alongside a well-known partner protein (PGC-1α) that endurance exercise itself activates. By turning the ERR dial up directly with a drug, the idea goes, you skip the workout and still send muscle the "build more aerobic capacity" instruction. That is a genuinely elegant target, and it is also why a single compound can plausibly affect endurance, fat handling, and blood-sugar control at once. The same breadth, however, is the reason caution is warranted: a switch this central does not act on only one tissue.

Here is what each piece contributes, in simple terms:

• ERR activation (the trigger): SLU-PP-332 binds the ERRs and recruits the cell's gene-activating machinery, switching on the exercise-response program.
• Mitochondrial biogenesis (more power plants): the program drives cells to build more mitochondria, raising their capacity to produce energy aerobically.
• Fat and sugar burning (fuel use): treated cells lean harder on oxidative metabolism, burning fatty acids and glucose rather than storing them.
• Muscle-fiber shift (endurance type): in mice, the compound increased type IIa oxidative muscle fibers, the kind associated with stamina rather than raw power.

The receptor-and-transcription deep dive (exactly how ERRα coordinates the gene network, why a pan-agonist hits three receptors) is its own topic. We keep it at overview level here and link out to how cellular signaling drives these effects for the foundations.

What did the SLU-PP-332 mouse studies actually show?

In 2023, mice given SLU-PP-332 ran far longer and farther without training, and obese mice lost weight and gained much less fat, which is exactly why it was nicknamed "exercise in a pill." Those are genuinely striking numbers, but they are mouse numbers, and that distinction is the heart of the promise-versus-proof story.

The endurance result came first. Saint Louis University and University of Florida researchers reported that normal-weight mice given SLU-PP-332 ran about 70% longer and 45% farther than untreated mice during a treadmill test, alongside an increase in fatigue-resistant oxidative muscle fibers (University of Florida News, "Exercise-mimicking drug sheds weight, boosts muscle activity in mice," 2023, retrieved 2026-06-16). A companion line of work looked at metabolism: in obese mice fed a high-fat diet and treated for about a month, the compound reduced obesity and improved insulin sensitivity, with treated animals gaining roughly ten times less fat than controls and losing about 12% of body weight (Journal of Pharmacology and Experimental Therapeutics, "A Synthetic ERR Agonist Alleviates Metabolic Syndrome," 2024, retrieved 2026-06-16).

A quick overview of what the mouse studies reported, and where each result stands:

Notice the bottom row. Every benefit lives in mice; the human row is blank, and we have left it blank on purpose. Because each of these directions (endurance, metabolic, future human work) could become its own future spoke, we keep them brief here.

How strong is the evidence for SLU-PP-332?

The evidence for SLU-PP-332 is early and entirely preclinical: a handful of mouse and laboratory studies, and zero human trials, so it sits on the lowest rung of the evidence ladder. This is the single most important section of the page. The promise is real on paper; the proof in people does not exist yet.

Researchers themselves frame it as an early lead compound, not a finished drug. A 2026 chemistry paper set out to fix SLU-PP-332's poor "drug-like" properties, reporting that it has very low solubility (around 0.2 micromolar) and a short half-life in human-liver-microsome tests (about 31 minutes), which is part of why it needed to be injected in mice and why the team designed improved successor molecules (International Journal of Biological Macromolecules, "Chemical optimization of the exercise mimetic SLU-PP-332," 2026, retrieved 2026-06-16). In other words, the compound that made the headlines is, by its inventors' own account, not ready for human use without redesign.

Why "no human data" is the headline, not a footnote

It is worth being blunt about how empty the human file is. As of 2026 there are no published human clinical trials of SLU-PP-332, no human pharmacokinetic data (we do not know how a person would absorb, distribute, or clear it), and therefore no human safety or efficacy record of any kind. That is a more complete absence than even most early research peptides, where at least small pilot studies sometimes exist. Translating a mouse result to a person is famously unreliable: many compounds that transform rodent metabolism do nothing useful, or cause harm, in humans, and a transcription factor as broad as ERR touches many tissues at once, which is precisely the kind of wide reach that can produce unexpected effects. Until a real human study is designed, run, and published, "investigational" is generous; "untested in humans" is the accurate label.

There is also a difference between the compound being interesting and the compound being ready. Reading the 2023 and 2024 papers alongside the 2026 chemistry work, the arc is clear: the original molecule was a proof of concept that the ERR target can be hit pharmacologically and that doing so reshapes metabolism in animals. The follow-up work then treated SLU-PP-332's weaknesses (its solubility and short half-life) as problems to engineer around with new analogs, rather than as obstacles already solved. For a reader, that sequence is reassuring about the science and sobering about the timeline: the people closest to the molecule are still in the "make it into a viable drug candidate" phase, which sits well before the first human dose, let alone a proven benefit.

Our take: The most common mistake we see is reading "exercise in a pill" as if it were a product you could evaluate like creatine or a GLP-1 drug. It is not. SLU-PP-332 is a promising mouse result and an early chemistry lead, full stop. The gap between "mice ran 70% longer" and "this is safe and effective for a person" is the entire story, and right now that gap is unbridged.

What doses of SLU-PP-332 were used in research?

There is no human dose for SLU-PP-332 because it has never been given to a person; in the mouse studies it was administered by injection (intraperitoneal), dosed about twice a day, over roughly a month for the metabolic work. Any number you see attached to a human "protocol" online is extrapolation, not data, and we will not invent one.

What the literature does describe is the animal route and schedule: the mouse studies used injection rather than oral capsules, and the metabolic study ran treatment for about a month with twice-daily dosing (Journal of Pharmacology and Experimental Therapeutics, 2024, retrieved 2026-06-16). The exact milligram-per-kilogram figures used in mice are reported inconsistently across secondary write-ups, and the primary abstracts we could access did not state a clean human-translatable dose, so we deliberately do not publish a specific mg/kg number rather than risk passing along an unverified one. Crucially, mouse doses do not convert simply to human doses, and an injected research-grade compound with a short half-life is exactly the kind of thing that cannot be responsibly "dosed" outside a controlled study.

For orientation only, here is how the research administration compares to what gray-market sellers imply (this is context, not a recommendation):

Our take: Sellers often list SLU-PP-332 as an oral capsule with a tidy daily dose, sometimes even calling it a "peptide." Both framings are misleading. It is a small molecule, it was injected in the actual studies, its inventors flagged its poor oral drug-likeness, and there is no human dose because there has been no human study. A confident dosing chart is the clearest sign a source is guessing.

What are the side effects and safety risks of SLU-PP-332?

Because SLU-PP-332 has never been tested in humans, its side-effect profile is completely unknown; "no human safety data" is the honest answer, and that is a risk in itself. There is no list of common side effects to report because the studies that would generate one have not been done.

What we can describe is the shape of the risk rather than specific effects. SLU-PP-332 activates the estrogen-related receptors, a family of transcription factors active in many tissues including muscle, heart, and metabolic organs, so a systemic agonist could plausibly affect more than the intended targets, and broad metabolic and transcriptional reach is precisely where unexpected long-term effects tend to appear (ACS Chemical Biology, 2023, retrieved 2026-06-16). On top of the biology, the unregulated market adds its own hazards. A hub-level overview of what is and is not known:

• Human side effects: unknown. No human has been studied, so there is no measured profile, mild or serious.
• Mechanism-based concerns (theoretical): ERRs act across many tissues; a broad agonist could have off-target metabolic or cardiac effects that only long-term human study would reveal.
• Drug-likeness concerns: researchers reported poor solubility and a short half-life, which is why the compound is not yet considered usable as a human medicine (International Journal of Biological Macromolecules, 2026, retrieved 2026-06-16).
• Quality and contamination risks: because the market is unregulated, mislabeled potency, impurities, and non-sterile product are real concerns independent of the molecule itself.

This is the hub-level summary. The deeper safety discussion (the specific ERR-tissue concerns and how researchers frame them) is a candidate future spoke; for now the headline is unchanged: there is no safety data in people.

Is SLU-PP-332 legal, and how do people get it?

SLU-PP-332 is not approved by any regulator, is not a supplement, and is not legal to sell or use as a medicine; the vials available online are unapproved "research chemicals" sold for laboratory use only. That status, not any single mouse result, is what matters most for a reader thinking about it.

There is no legitimate way to obtain SLU-PP-332 as a medicine, because it is not one: there is no approved product, no prescription pathway, and outside a formal research setting no oversight at all. What exists instead is a gray market of vendors selling the powder "for research use only, not for human consumption," which buyers sometimes use off-label (Cayman Chemical, SLU-PP-332 product listing, 2026, retrieved 2026-06-16). That market carries the familiar risks of any unregulated research chemical, including uncertain identity, mislabeled potency, and impurities, with no one standing behind the product. Athletes should also note that broad metabolic and "exercise mimetic" agents draw anti-doping scrutiny, so anyone subject to testing should treat an experimental ERR agonist as high-risk by default. For the general legal picture and how to evaluate any research compound, see the research-chemical legal status explainer and how to read a certificate of analysis.

Our take: The single most common misunderstanding is assuming that because SLU-PP-332 is easy to buy and surrounded by exciting science, it must be a vetted product. It is the opposite: it is an early-stage research molecule that has never been in a human, sold without oversight. Easy to order is not the same as tested, legal, or safe.

How does SLU-PP-332 relate to other "exercise mimetics"?

SLU-PP-332 is one of several experimental "exercise mimetic" compounds, but it works through a different target (the ERR transcription factors) than the others, and like them it is unproven in humans for this purpose. It is best understood as part of a research class, not a category leader.

Other compounds discussed as exercise mimetics include GW501516 (often sold as Cardarine, which acts on a different receptor called PPARδ) and AICAR (which activates an energy sensor called AMPK). SLU-PP-332 is mechanistically distinct from both because it targets the ERRs, and its own inventors have already developed optimized successor molecules to address its drug-likeness problems (International Journal of Biological Macromolecules, 2026, retrieved 2026-06-16). We are deliberately keeping this brief: each of those compounds is its own topic with its own evidence and legal issues, and a full comparison belongs in a dedicated article rather than here. The shared honest caveat applies to the whole class: exciting mechanisms, little or no human proof, and no regulatory approval for performance or fat loss.

The bottom line

SLU-PP-332 is one of the most genuinely interesting compounds in the metabolic-research world, and also one of the most over-sold. The science is real: it activates the ERR family to switch on an exercise-like gene program, and in 2023 that translated into mice running far longer and obese mice gaining far less fat. You can see why "exercise in a pill" wrote itself as a headline.

The other half of the story is the discipline the headline skips. Every result is in mice; there is no human trial, no human safety data, and no approved dose; the compound's own inventors call it not yet drug-like and have moved on to improved versions; and what is sold online is an unregulated research chemical, not a product anyone has vetted for people. Promise is abundant here. Proof, in humans, is currently zero. If you take one thing from this hub, let it be that distinction, and the value of waiting for actual human data rather than buying a mouse result. From here, the natural next reads are how to vet research-compound quality, are these compounds legal, and how these compounds signal in the body.

Frequently Asked Questions

Sources

• ACS Chemical Biology. "Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity." 2023. Retrieved 2026-06-16. https://pubs.acs.org/doi/abs/10.1021/acschembio.2c00720
• University of Florida News. "Exercise-mimicking drug sheds weight, boosts muscle activity in mice." 2023. Retrieved 2026-06-16. https://news.ufl.edu/2023/09/exercise-mimicking-drug/
• ScienceDaily. "Exercise-mimicking drug sheds weight, boosts muscle activity in mice." 2023. Retrieved 2026-06-16. https://www.sciencedaily.com/releases/2023/09/230925153752.htm
• Journal of Pharmacology and Experimental Therapeutics. "A Synthetic ERR Agonist Alleviates Metabolic Syndrome." 2024. Retrieved 2026-06-16. https://jpet.aspetjournals.org/article/S0022-3565(24)17158-3/abstract
• International Journal of Biological Macromolecules. "Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling." 2026. Retrieved 2026-06-16. https://pmc.ncbi.nlm.nih.gov/articles/PMC13112601/
• Wikipedia. "SLU-PP-332." Retrieved 2026-06-16. https://en.wikipedia.org/wiki/SLU-PP-332
• PubChem. "SLU-PP-332 (CID 5404083)." Retrieved 2026-06-16. https://pubchem.ncbi.nlm.nih.gov/compound/5404083
• Cayman Chemical. "SLU-PP-332 (Item 41719)." 2026. Retrieved 2026-06-16. https://www.caymanchem.com/product/41719/slu-pp-332